AN2 Therapeutics, Inc. - Common Stock (ANTX)

CUSIP: 037326105

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 5 signals
Share change
+281
SEC-reported price per share
$5.32
Number of holders
2
Value change
+$1,495
Number of buys
2
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
36,076,317

Security key

037326105

Report period

Q3 2026

Institutions

2

Top holders

2

Ownership snapshot

Top reported holders of ANTX - AN2 Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Commodore Capital LP
Disclosed value leader
Adjuvant Global Health Te...
Comparable rows
9/15
Latest evidence
30 Jun 2026
13F 13D/G 3/4/5 Lead comparable stake: 9.9% 6 rows are not safely comparable across share classes. 13D/G row: Commodore Capital LP Showing 1-6 of 15 holder rows.

Quick read

Commodore Capital LP leads the comparable SEC ownership view at 9.9%.

9 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Commodore Capital LP's linked filing trail.
Comparable ownership Top 5
Commodore Capital LP 9.9%
Coastlands Capital Partners LP 9.3%
Vivo Opportunity Fund Holdings, L.P. 8%
Adjuvant Global Health Technology... 7.9%
Eric Easom 7.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Commodore Capital LP
13F 13D/G
Company
9.9%
Reported 13D/G · 09 Mar 2026
$14,199,011
2,933,680 shares
— 30 Jun 2026
Coastlands Capital Partners LP
13D/G
Coastlands Capital LP
9.3%
Reported 13D/G · 28 May 2025
$3,632,511
2,815,900 shares
$0 28 May 2025
Vivo Opportunity Fund Holdings, L.P.
13D/G
8%
Reported 13D/G · 10 Mar 2026
$3,780,937
2,864,346 shares
$0 10 Mar 2026
Adjuvant Global Health Technology Fund, L.P.
3/4/5 13D/G
10%+ Owner · Adjuvant Capital GP, L.P.
7.9%
Reported 13D/G · 31 Dec 2024
$45,367,317
2,373,500 shares
— 16 Jan 2024
Eric Easom
13D/G 3/4/5
Chief Executive Officer, Director
7.9%
Reported 13D/G · 31 Dec 2025
$2,946,245
2,232,004 shares
+$447,311 31 Dec 2025
INTEGRATED CORE STRATEGIES (US) LLC
13D/G
Millennium Management LLC
6.3%
Reported 13D/G · 06 Mar 2026
$2,952,975
2,237,102 shares
$0 06 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
2
Shares
281
Rows available
2
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
66
Q3 2026 holders
2
Holder diff
-64
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .